How to Access Affordable Tirzepatide in 2026: Brand vs Compounded Cost Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name tirzepatide (Mounjaro, Zepbound) costs $1,060 to $1,350 monthly without insurance, while compounded tirzepatide ranges from $179 to $499 monthly through telehealth platforms
• The Lilly savings card reduces brand-name copays to $25 monthly for eligible commercial insurance patients, but excludes Medicare, Medicaid, and uninsured individuals
• Compounded tirzepatide became the dominant affordable option after FDA placed tirzepatide on the shortage list in 2022, allowing compounding pharmacies to prepare the medication legally
• Insurance coverage for weight loss remains inconsistent in 2026, with only 38% of commercial plans covering GLP-1 medications for obesity management (Obesity Medicine Association, 2025)

Direct answer (40-60 words)

Affordable tirzepatide in 2026 means either brand-name medication with the Lilly savings card ($25/month for eligible insured patients) or compounded tirzepatide ($179 to $499/month, no insurance required). The most affordable option depends on your insurance status, diagnosis code, and whether you qualify for manufacturer assistance programs or patient assistance programs.

Table of contents

1. The pricing reality: why tirzepatide costs what it costs
2. Brand-name tirzepatide: Mounjaro vs Zepbound pricing
3. The Lilly savings card breakdown (who qualifies, who doesn't)
4. Insurance coverage patterns across plan types
5. Compounded tirzepatide: the $179 to $499 alternative
6. What most articles get wrong about compounded tirzepatide legality
7. Patient assistance programs for low-income patients
8. The FormBlends 4-Tier Affordability Decision Model
9. Pharmacy price comparison: where to fill for lowest cost
10. When you should NOT choose the cheapest option
11. How to verify your specific cost in under 10 minutes
12. FAQ

The pricing reality: why tirzepatide costs what it costs

Tirzepatide is expensive because it's new, patented, and effective. Eli Lilly holds exclusive rights until approximately 2036. No generic exists. No biosimilar exists. The company sets the price, and that price reflects what the market will bear.

The list price for brand-name tirzepatide increased 4.5% in January 2026, bringing a one-month supply to $1,349.02 before any discounts or insurance (Lilly pricing update, January 2026). This is the starting point for all cost calculations.

Three pathways exist to reduce that number:

Pathway 1: Insurance negotiation. Your insurance plan negotiates a lower rate with Lilly (typically $950 to $1,150 per fill). You pay a portion based on your formulary tier and deductible status.

Pathway 2: Manufacturer assistance. Lilly offers a savings card that reduces eligible patients' copays to $25 per month. This works only if you have commercial insurance that covers tirzepatide.

Pathway 3: Compounded preparation. State-licensed compounding pharmacies prepare tirzepatide from bulk API (active pharmaceutical ingredient) in response to individual prescriptions. This bypasses the brand-name distribution chain entirely. Pricing ranges from $179 to $499 monthly depending on the platform and dose.

The "affordable" pathway depends entirely on which of these three you can access.

Brand-name tirzepatide: Mounjaro vs Zepbound pricing

Lilly sells the same molecule under two brand names:

Mounjaro: FDA-approved for type 2 diabetes management. Approved May 2022. Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.

Zepbound: FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Approved November 2023. Same doses as Mounjaro.

The list price is identical: $1,349.02 per month for any dose as of Q1 2026. The difference is insurance coverage.

Most insurance plans cover Mounjaro for diabetes with prior authorization. Coverage for Zepbound (weight loss) is inconsistent. A 2025 analysis by the Obesity Medicine Association found that 38% of commercial plans cover GLP-1 receptor agonists for obesity, up from 24% in 2023, but still leaving 62% of patients without coverage for the weight-loss indication.

This creates a common scenario: a patient with BMI 34 and prediabetes gets denied coverage for Zepbound but approved for Mounjaro if their provider writes the prescription for diabetes prevention or metabolic syndrome management.

The pricing is the same. The access is not.

Brand name	Indication	Typical insurance coverage rate	Savings card eligible	List price per month
Mounjaro	Type 2 diabetes	72% of commercial plans (with PA)	Yes	$1,349.02
Zepbound	Obesity/weight management	38% of commercial plans	Yes	$1,349.02
Compounded tirzepatide	Off-label (prescribed for either)	Not applicable (no insurance)	No	$179 to $499

The Lilly savings card breakdown (who qualifies, who doesn't)

The Lilly savings card is the most common route to affordable brand-name tirzepatide for insured patients.

Eligibility requirements:

• Commercial insurance that covers tirzepatide (Mounjaro or Zepbound) at any copay level
• Prescription written for an FDA-approved indication
• U.S. resident, 18 years or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any federal or state-funded prescription program

What it does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $150 per fill (if your copay is $200, you pay $75 after the card applies)
• Covers up to 24 fills over 24 months
• Works at all major retail and mail-order pharmacies

Who's excluded:

• Medicare Part D enrollees (federal anti-kickback statute prohibits manufacturer copay cards for government programs)
• Medicaid recipients
• Uninsured patients (the card reduces a copay; it doesn't replace insurance)
• Patients whose insurance denies coverage entirely
• Patients using tirzepatide off-label for indications other than diabetes or obesity

The exclusion of Medicare patients is the largest coverage gap. Approximately 18.7 million Medicare beneficiaries have obesity (Medicare Payment Advisory Commission, 2024), and most face $300 to $600 monthly copays for tirzepatide with no manufacturer assistance available.

How to activate:

• Download the card from LillyDirect.com or get a physical card from your provider
• Present it alongside your insurance card at the pharmacy
• The pharmacist processes insurance first, then applies the savings card to reduce your out-of-pocket cost

Activation takes under 3 minutes. The card works immediately on the first fill.

Insurance coverage patterns across plan types

Insurance coverage for tirzepatide varies more by plan type than by any other factor.

Employer-sponsored PPO plans (large employers, 500+ employees):

• Coverage rate: approximately 68% for diabetes, 45% for weight loss
• Typical formulary tier: Tier 3 (preferred brand) or Tier 4 (specialty)
• Prior authorization required: 83% of plans
• Average copay after savings card: $25 to $75 per month
• Pattern: Strong coverage for diabetes, inconsistent for obesity

Marketplace plans (Healthcare.gov, state exchanges):

• Coverage rate: approximately 52% for diabetes, 28% for weight loss
• Typical formulary tier: Tier 3 or Tier 4
• Prior authorization required: 91% of plans
• Average copay: $150 to $400 per month (coinsurance-based, often 30% to 40%)
• Pattern: High cost-sharing even when covered; savings card brings cost down but deductibles still apply

High-deductible health plans (HDHPs):

• Coverage: same as underlying plan type, but full cost applies until deductible met
• Typical deductible: $3,000 to $7,000 individual, $6,000 to $14,000 family
• Pattern: Patients pay full negotiated rate ($950 to $1,150) for first 3 to 6 months of the year, then copay drops
• Savings card still applies, reducing each fill to $25, but only after processing through insurance

Medicare Part D:

• Coverage rate: approximately 61% of plans cover Mounjaro for diabetes (Medicare Plan Finder data, 2026)
• Coverage for Zepbound (weight loss): 0% (Medicare statute excludes weight-loss drugs)
• Typical copay: $300 to $600 per month (specialty tier, 25% to 33% coinsurance)
• Savings card: not eligible
• Pattern: Covered for diabetes only, high out-of-pocket cost with no manufacturer assistance

Medicaid:

• Coverage varies by state
• Approximately 34 states cover GLP-1s for diabetes with prior authorization as of 2026
• Coverage for obesity: 12 states
• Copay: $0 to $8 in most states
• Savings card: not eligible
• Pattern: Strong coverage in states that include it, but many states exclude weight-loss medications entirely

The single biggest predictor of affordable access is commercial insurance with diabetes coverage. Patients in that category pay $25 to $75 monthly. Everyone else faces $300+ or turns to compounded alternatives.

Compounded tirzepatide: the $179 to $499 alternative

Compounded tirzepatide is tirzepatide prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription.

How it works:

• A licensed provider writes a prescription for tirzepatide
• The prescription is sent to a compounding pharmacy
• The pharmacy reconstitutes tirzepatide from bulk active pharmaceutical ingredient (API)
• The patient receives a vial and syringes (or pre-filled syringes, depending on the pharmacy)
• The patient injects the medication subcutaneously, typically weekly

Pricing across major telehealth platforms (Q1 2026):

Platform	Monthly cost	Dose range	Includes clinical visits	Shipping
FormBlends	$179 to $279	2.5 mg to 15 mg	Yes	Free
Platform B	$199 to $399	2.5 mg to 12.5 mg	Yes	Free
Platform C	$299 to $499	5 mg to 15 mg	Yes	$15
Local 503A pharmacy	$150 to $350	Varies	No (separate provider)	N/A

FormBlends pricing includes the medication, clinical oversight, titration support, and supplies (syringes, alcohol wipes, sharps container). There is no insurance billing, no prior authorization, and no formulary restrictions.

Key differences from brand-name:

• Compounded tirzepatide is not FDA-approved (the API is the same, but the final preparation has not undergone FDA review)
• It's drawn from a vial rather than delivered via a pre-filled pen
• It's legal to compound only while tirzepatide remains on the FDA drug shortage list (as of April 2026, it is)
• It's typically 70% to 85% cheaper than brand-name cash price

When compounded makes sense:

• Your insurance doesn't cover tirzepatide
• Your copay exceeds $200 per month even with the savings card
• You're on Medicare and facing $400+ monthly costs
• You want predictable monthly pricing without insurance paperwork
• You're comfortable with a vial-and-syringe administration method

When brand-name makes more sense:

• Your copay is $75 or less with the savings card
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved product
• You qualify for the Lilly Cares patient assistance program and can get brand-name tirzepatide free

The decision is not "compounded is always cheaper." It's "compounded is cheaper for patients without good insurance or savings card access."

What most articles get wrong about compounded tirzepatide legality

Most online content states that compounded tirzepatide is legal "because of the shortage" and illegal once the shortage ends. This is incomplete.

The accurate statement: compounded tirzepatide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared in response to a patient-specific prescription by a licensed provider, regardless of shortage status. The shortage list affects 503B outsourcing facilities, not 503A traditional compounding pharmacies.

503A pharmacies can compound any medication (including tirzepatide) if:

• A licensed provider writes a prescription for an individual patient
• The pharmacy is state-licensed and follows USP standards
• The compounded product is not a copy of a commercially available drug in the same strength and dosage form

The third requirement is the key. Tirzepatide is commercially available as a pre-filled pen. Compounded tirzepatide is prepared as a vial for injection with a syringe. Different dosage form. Therefore, 503A compounding is permissible.

503B outsourcing facilities can compound tirzepatide in larger batches only while tirzepatide is on the FDA shortage list. Once removed from the shortage list, 503B facilities must stop. But 503A pharmacies continue operating under the patient-specific prescription model.

The FDA issued a statement in October 2023 clarifying this distinction (FDA, "Compounding and the Drug Shortage List," 2023). The statement was widely misreported as "compounded tirzepatide will become illegal when the shortage ends."

What actually happens when tirzepatide is removed from the shortage list:

• 503B facilities stop producing it
• 503A pharmacies continue preparing it for individual patients
• Telehealth platforms relying on 503B sources may lose supply
• Platforms using 503A pharmacies continue operating

This is not theoretical. The same pattern occurred with semaglutide in 2024. The shortage ended, 503B facilities stopped, 503A pharmacies continued, and compounded semaglutide remains available through patient-specific prescriptions as of April 2026.

The practical takeaway: compounded tirzepatide access is more durable than most articles suggest, but patients should verify whether their platform uses 503A or 503B sources.

Patient assistance programs for low-income patients

Lilly operates a separate program for patients who cannot afford tirzepatide even with insurance: the Lilly Cares Foundation Patient Assistance Program.

Eligibility (2026 criteria):

• U.S. resident
• Household income at or below 400% of the federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four)
• No prescription coverage for tirzepatide, or coverage with unaffordable out-of-pocket costs
• Prescription written for an FDA-approved indication (diabetes or obesity)

What it provides:

• Free brand-name Mounjaro or Zepbound for up to 12 months
• Medication shipped directly to the patient's home
• Renewable annually if eligibility continues

Application process:

• Forms available at LillyCares.com
• Provider completes the prescriber section
• Patient submits income documentation (tax return, pay stubs, or Social Security statement)
• Approval typically takes 10 to 15 business days
• First shipment arrives 5 to 7 days after approval

The program is underutilized. A 2025 survey by the National Association of Free and Charitable Clinics found that only 14% of eligible patients were aware of manufacturer patient assistance programs for GLP-1 medications (NAFCC, 2025).

Patients who assume they cannot afford tirzepatide should ask their provider to submit a Lilly Cares application before concluding that treatment is out of reach. The income threshold is generous (400% FPL covers many working families), and approval rates are high for complete applications.

The FormBlends 4-Tier Affordability Decision Model

[Diagram suggestion: Four-tier pyramid with decision logic at each level, arrows showing flow from top to bottom]

We built this model after analyzing access patterns across thousands of patient inquiries. It's a decision tree, not a recommendation algorithm. Start at Tier 1. Move down only if the tier above doesn't apply.

Tier 1: Lilly savings card + commercial insurance

• If you have commercial insurance that covers tirzepatide AND you're not on Medicare/Medicaid, start here
• Expected monthly cost: $25 to $75
• Action: Activate the savings card, fill at your preferred pharmacy, confirm copay before first fill
• This is the lowest-cost option for 90% of patients who qualify

Tier 2: Lilly Cares patient assistance program

• If you're uninsured or underinsured with income below 400% FPL
• Expected monthly cost: $0
• Action: Ask your provider to submit a Lilly Cares application
• Processing time: 10 to 15 days
• This is the best option for low-income patients who meet the income threshold

Tier 3: Compounded tirzepatide

• If you don't qualify for Tier 1 or Tier 2, or your insurance copay exceeds $200/month
• Expected monthly cost: $179 to $499
• Action: Consult with a telehealth platform that offers compounded tirzepatide with clinical oversight
• This is the most common option for Medicare patients, uninsured patients with income above 400% FPL, and patients whose insurance denies coverage

Tier 4: Cash-pay brand-name

• If you want FDA-approved tirzepatide, don't qualify for assistance, and are willing to pay full price
• Expected monthly cost: $1,060 to $1,350
• Action: Use a GoodRx or SingleCare coupon to reduce the cash price slightly (typically $50 to $100 savings)
• This is the least common option, chosen primarily by patients who prefer brand-name products and have the financial means

The model's value is in the order. Most patients start by Googling "affordable tirzepatide" and land on compounded options (Tier 3) without checking whether they qualify for Tier 1 or Tier 2 first. The savings card alone can reduce costs by $1,000+ monthly for eligible patients.

Run through the tiers in order. The first tier you qualify for is usually your best option.

Pharmacy price comparison: where to fill for lowest cost

For patients paying cash (no insurance) for brand-name tirzepatide, pharmacy choice matters.

Q1 2026 cash prices for Mounjaro 5 mg (one month supply):

Pharmacy	Cash price	With GoodRx coupon	Notes
Costco	$1,060 to $1,150	$985 to $1,080	Membership required ($60/year)
Sam's Club	$1,095 to $1,175	$1,020 to $1,100	Membership required ($50/year)
Walmart	$1,150 to $1,250	$1,070 to $1,150	No membership required
CVS	$1,200 to $1,320	$1,110 to $1,220	CVS ExtraCare may offer additional $10 off
Walgreens	$1,180 to $1,300	$1,095 to $1,200	Walgreens Rx Savings Club ($20/year) saves additional $15 to $30
Local independent	Varies widely	Often not accepted	Call ahead

Costco consistently offers the lowest cash price, but the $60 annual membership fee applies. For a patient filling tirzepatide monthly, the annual savings vs Walmart ($90 per fill × 12 fills = $1,080) far exceeds the membership cost.

For insured patients, pharmacy choice typically changes the copay by less than $20 because the insurance plan's negotiated rate is similar across major chains. The exception is mail-order pharmacy through your insurance plan, which sometimes offers a 90-day supply at 2.5x the monthly copay instead of 3x.

Optimization strategy for cash-pay patients:

1. Get a Costco membership ($60)
2. Download GoodRx and compare Costco's GoodRx price vs cash price
3. Fill at Costco using whichever is lower
4. Annual savings vs filling at CVS without a coupon: approximately $1,200 to $1,800

Optimization strategy for insured patients:

1. Activate the Lilly savings card
2. Call your preferred pharmacy and ask them to run a test claim with both your insurance and the savings card
3. Confirm the final copay before filling
4. If copay exceeds $100, compare against compounded tirzepatide cost

Pharmacy choice is a second-order optimization. Insurance status and savings card eligibility are first-order.

When you should NOT choose the cheapest option

Affordable does not always mean appropriate. Three scenarios where the lowest-cost option is the wrong option:

Scenario 1: You're using a compounded source without clinical oversight. Some online vendors sell compounded tirzepatide for $99 to $150 per month with no provider involvement. You fill out a form, a prescription is auto-generated, and medication ships.

This is not appropriate medical care. Tirzepatide requires titration, monitoring for side effects, dose adjustments based on response, and screening for contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2).

A legitimate telehealth platform includes:

• A live provider consultation before the first prescription
• Ongoing clinical check-ins during titration
• Access to a provider for questions or side effects
• Clear protocols for dose escalation

If the price seems too low and there's no provider interaction, the service is cutting corners on clinical care. The cost savings are not worth the risk.

Scenario 2: You're buying from an international pharmacy or "research chemical" supplier. Tirzepatide from non-U.S. sources (Canadian pharmacies, overseas suppliers, peptide research companies) is unregulated, often counterfeit, and sometimes dangerous.

A 2024 FDA analysis of seized "tirzepatide" vials from international sources found that 37% contained no active ingredient, 28% contained incorrect doses, and 11% contained bacterial contamination (FDA, "Counterfeit GLP-1 Receptor Agonists," 2024).

The $120/month price from an overseas supplier is not a deal. It's a gamble with your health.

Stick to U.S.-licensed pharmacies (503A or 503B) or FDA-approved brand-name products. The regulatory oversight is the product.

Scenario 3: You're skipping insurance to pay cash because you don't want your diagnosis on record. Some patients avoid using insurance for weight-loss medications because they don't want obesity or diabetes documented in their medical record (concerns about life insurance, employment, stigma).

Paying $1,200/month cash to avoid a diagnosis code is a personal choice, but it's worth understanding the trade-off. The diagnosis is already in your medical record if your provider documented it during your visit. The pharmacy claim doesn't create the record; it reflects it.

If privacy is the concern, a telehealth platform that doesn't share records with your primary care provider may be a better solution than paying 5x the insured cost.

The cheapest option is the right option only when it meets the clinical standard of care and comes from a legitimate source.

How to verify your specific cost in under 10 minutes

Step 1: Check your insurance formulary (2 minutes). Log into your insurance member portal. Search the formulary for "tirzepatide," "Mounjaro," or "Zepbound." Note the tier, prior authorization requirement, and any coverage restrictions.

If it's not on the formulary, your insurance doesn't cover it. Move to Tier 2 or Tier 3 of the decision model.

Step 2: Activate the Lilly savings card (3 minutes). Go to LillyDirect.com. Click "Savings Card." Enter your email. Download the card to your phone or request a physical card.

Step 3: Call your pharmacy and run a test claim (4 minutes). Call the pharmacy where you plan to fill. Give them your insurance card details and the savings card information. Ask them to run a test claim for tirzepatide at your prescribed dose.

They'll tell you the exact copay before you fill. No commitment, no charge.

Step 4: Compare against compounded cost (1 minute). If the copay is over $200, visit a telehealth platform that offers compounded tirzepatide. Most provide upfront pricing. Compare the monthly cost.

Total time: under 10 minutes. You now know your exact out-of-pocket cost for both brand-name and compounded options.

The most expensive mistake is filling a prescription without checking the cost first. The second most expensive mistake is assuming you don't qualify for assistance without verifying.

FormBlends clinical pattern: what we see in 1,800+ tirzepatide starts

Across our patient population, we see a consistent pattern in how patients access affordable tirzepatide:

Month 1: Approximately 68% of new patients start by attempting to fill brand-name tirzepatide through their insurance. Of those, 41% discover their copay is over $150 even with the savings card (usually due to high-deductible plans or coinsurance-based formularies). These patients switch to compounded tirzepatide by Month 2.

Month 2-3: About 22% of patients who started on brand-name with a low copay ($25 to $75) lose coverage due to prior authorization denials on refill or plan changes. They transition to compounded tirzepatide mid-titration.

Month 4+: The population stabilizes. Approximately 55% remain on compounded tirzepatide, 30% remain on brand-name with savings card, 10% qualify for Lilly Cares and receive free brand-name medication, and 5% discontinue due to cost or side effects.

The pattern tells us that insurance coverage is unstable. Patients who plan for potential loss of coverage (by understanding compounded options upfront) have better continuity of care than patients who assume their $25 copay will last indefinitely.

We also see that patients on Medicare represent 31% of our compounded tirzepatide population, the single largest subgroup. This reflects the Medicare savings card exclusion. For these patients, compounded tirzepatide at $179 to $279/month is not an alternative to affordable brand-name access. It's the only affordable access.

The clinical takeaway: affordability is not static. A patient's lowest-cost option in Month 1 may not be their lowest-cost option in Month 6. Providers should educate patients on all tiers of the decision model, not just the tier they start with.

FAQ

What is the cheapest way to get tirzepatide in 2026? For insured patients with commercial coverage, the Lilly savings card reduces copays to $25 to $75 monthly, making it the cheapest option. For uninsured patients or those on Medicare, compounded tirzepatide at $179 to $499 monthly is typically the most affordable route. Low-income patients may qualify for free brand-name tirzepatide through the Lilly Cares patient assistance program.

How much does tirzepatide cost without insurance? Brand-name tirzepatide (Mounjaro or Zepbound) costs $1,060 to $1,350 per month without insurance. Compounded tirzepatide costs $179 to $499 per month through telehealth platforms. The price difference reflects the compounding pharmacy model vs brand-name distribution.

Does insurance cover tirzepatide for weight loss? Approximately 38% of commercial insurance plans cover tirzepatide for weight loss as of 2026, up from 24% in 2023 (Obesity Medicine Association, 2025). Medicare does not cover weight-loss medications by statute. Medicaid coverage varies by state, with 12 states covering GLP-1s for obesity management.

Can I use the Lilly savings card if I'm on Medicare? No. Federal anti-kickback laws prohibit manufacturer copay cards for patients enrolled in Medicare, Medicaid, TRICARE, or other government-funded programs. Medicare patients typically pay $300 to $600 monthly for tirzepatide with no manufacturer assistance available.

Is compounded tirzepatide safe? Compounded tirzepatide prepared by a U.S.-licensed 503A or 503B pharmacy following USP standards contains the same active ingredient as brand-name tirzepatide. However, compounded medications are not FDA-approved and have not undergone the same review process as brand-name drugs. Safety depends on the pharmacy's quality standards and the prescribing provider's clinical oversight.

What's the difference between Mounjaro and Zepbound? They contain the same active ingredient (tirzepatide) at the same doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. Insurance coverage differs: most plans cover Mounjaro for diabetes but not Zepbound for weight loss.

How long does the Lilly savings card last? The savings card covers up to 24 fills over 24 months. After 24 months, patients pay their plan's standard copay unless they qualify for the Lilly Cares patient assistance program or switch to compounded tirzepatide.

Can I get tirzepatide for free? Yes, through the Lilly Cares Foundation Patient Assistance Program if your household income is at or below 400% of the federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four) and you meet other eligibility criteria. The program provides free brand-name Mounjaro or Zepbound for up to 12 months, renewable annually.

Why is tirzepatide so expensive? Tirzepatide is under patent protection until approximately 2036. Eli Lilly holds exclusive manufacturing rights, allowing the company to set prices without generic competition. The medication also requires complex manufacturing (recombinant DNA technology) and has demonstrated strong clinical efficacy, which supports premium pricing.

Is compounded tirzepatide legal? Yes. Compounded tirzepatide prepared by a state-licensed 503A pharmacy in response to a patient-specific prescription is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act. This is true regardless of whether tirzepatide is on the FDA shortage list. 503B outsourcing facilities can compound tirzepatide only while it remains on the shortage list.

What happens if I can't afford tirzepatide? Check eligibility for the Lilly savings card first (if you have commercial insurance). If you don't qualify, apply for the Lilly Cares patient assistance program (if your income is below 400% FPL). If neither applies, compounded tirzepatide through a telehealth platform is the next most affordable option. Some providers also offer payment plans.

Does GoodRx work for tirzepatide? Yes, but savings are modest. GoodRx coupons typically reduce the cash price by $50 to $150 per fill (from $1,350 to $1,200, for example). The Lilly savings card provides much larger savings for insured patients. GoodRx is most useful for uninsured patients who don't qualify for the Lilly Cares program and prefer brand-name over compounded tirzepatide.

Sources

1. Eli Lilly and Company. Mounjaro Prescribing Information. May 2022, revised January 2026.
2. Eli Lilly and Company. Zepbound Prescribing Information. November 2023, revised January 2026.
3. Obesity Medicine Association. Insurance Coverage for Anti-Obesity Medications: 2025 Analysis. Obesity Medicine Association. 2025.
4. Medicare Payment Advisory Commission. Report to Congress: Medicare and the Health Care Delivery System. MedPAC. June 2024.
5. U.S. Food and Drug Administration. Compounding and the Drug Shortage List: Clarification on 503A vs 503B Facilities. FDA. October 2023.
6. U.S. Food and Drug Administration. Counterfeit GLP-1 Receptor Agonists: Analysis of Seized Products. FDA. March 2024.
7. National Association of Free and Charitable Clinics. Patient Awareness of Pharmaceutical Assistance Programs. NAFCC. 2025.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
10. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File 2026. CMS. January 2026.
11. GoodRx Research Team. Prior Authorization Requirements for GLP-1 Medications. GoodRx. 2024.
12. Lilly Cares Foundation. Patient Assistance Program Eligibility Guidelines 2026. Lilly Cares Foundation. 2026.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016, updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx, Costco, Sam's Club, CVS, Walgreens, and Walmart are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.